MarketCapExport financials
Regeneron Pharmaceuticals (REGN)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Regeneron Pharmaceuticals Income Statement 2025-2007 | REGN
Brief overview of income trends at Regeneron Pharmaceuticals
This overview is based on financial performance over the past five years. Revenue at Regeneron Pharmaceuticals moved from $8.5 billion in 2020 to $14.3 billion in 2025. Overall revenue changed by +68.8%, equal to an annualized rate of about 11%. Top-line growth remained consistently strong over the period.
EBITDA was $3.8 billion at the beginning and $4.1 billion at the end of the period (+8.1%). EBITDA underperformed the top-line trend. At the operating-margin level, the figure shifted from 44.9% to 28.7%. The margin contraction indicates weaker operating efficiency.
The five-year change in net income was +28.2%: from 3.5 billion dollars to 4.5 billion dollars. Net income did not provide a strong directional signal.
The five-year change in capitalization reached +56.3%: from 52 billion dollars to 81.3 billion dollars. Higher capitalization indicates improving investor confidence.
What the figures show
The financial profile remains mixed, with strengths and risks moving in different directions. The constructive conclusion rests on revenue expansion and improving net profitability. Caution is warranted because of weaker operating efficiency. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.
Annual Income Statement Regeneron Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
81.3 B | 77.7 B | 100 B | 83.6 B | 66.8 B | 52 B | 36.7 B | 45.3 B | 40.4 B | 36.1 B | 43.3 B | 41.9 B | 28.7 B | 16.5 B | 8.05 B | 2.29 B | 1.23 B | - | - |
Shares |
105 M | 108 M | 107 M | 107 M | 106 M | 108 M | 109 M | 108 M | 106 M | 105 M | 103 M | 101 M | 97.9 M | 94.7 M | 90.6 M | 82.9 M | 78.9 M | - | - |
Historical Prices |
777 | 720 | 939 | 781 | 632 | 483 | 375 | 374 | 376 | 367 | 543 | 410 | 275 | 171 | 55.4 | 27.7 | 15.6 | 19.5 | 23 |
Net Income |
4.5 B | 4.41 B | 3.95 B | 4.34 B | 8.08 B | 3.51 B | 2.12 B | 2.44 B | 1.2 B | 896 M | 636 M | 348 M | 424 M | 750 M | -222 M | -104 M | -67.8 M | -79.1 M | - |
Revenue |
14.3 B | 14.2 B | 13.1 B | 12.2 B | 16.1 B | 8.5 B | 7.86 B | 6.71 B | 5.87 B | 4.86 B | 4.1 B | 2.82 B | 2.1 B | 1.38 B | 446 M | 459 M | 379 M | 238 M | - |
Cost of Revenue |
- | - | - | - | - | - | 403 M | 238 M | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | - | 7.08 B | 6.28 B | 5.48 B | 4.56 B | 3.71 B | 2.61 B | 1.95 B | 1.29 B | 442 M | - | - | - | - |
Operating Income |
3.58 B | 3.99 B | 4.05 B | 4.74 B | 8.95 B | 3.58 B | 2.21 B | 2.53 B | 2.08 B | 1.33 B | 1.25 B | 824 M | 743 M | 458 M | -205 M | -97.5 M | -74.1 M | -86.2 M | - |
Interest Expense |
1.7 B | 844 M | 73 M | 59.4 M | 57.3 M | 56.9 M | 30.2 M | 28.2 M | 25.1 M | 7.2 M | 14.2 M | 37.4 M | 46.4 M | 45.3 M | 21.3 M | 9.12 M | 2.34 M | 7.75 M | - |
EBITDA |
4.12 B | 4.47 B | 4.47 B | 5.08 B | 9.23 B | 3.81 B | 2.42 B | 2.68 B | 2.23 B | 1.44 B | 1.33 B | 891 M | 801 M | 495 M | -174 M | -77.8 M | -59.9 M | -75 M | - |
Operating Expenses |
- | - | - | - | - | - | 4.87 B | 3.74 B | 3.4 B | 3.23 B | 2.46 B | 1.78 B | 1.19 B | 836 M | 647 M | - | - | - | - |
General and Administrative Expenses |
2.7 B | 2.95 B | 2.63 B | 2.12 B | 1.82 B | 1.35 B | 1.83 B | 1.56 B | 1.32 B | 1.18 B | 839 M | 505 M | 329 M | 211 M | 117 M | 65.2 M | 52.9 M | 48.9 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Regeneron Pharmaceuticals
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
103 M | 104 M | 104 M | 105 M | 107 M | 108 M | 108 M | 108 M | 106 M | 107 M | 107 M | - | 107 M | 108 M | 107 M | - | 106 M | 105 M | 105 M | - | 106 M | 110 M | 110 M | - | 109 M | 109 M | 109 M | - | 108 M | 108 M | 108 M | - | 107 M | 106 M | 106 M | - | 105 M | 105 M | 104 M | - | 103 M | 103 M | 102 M | - | 101 M | 100 M | 98.7 M | - | 98.2 M | 97.7 M | 96.9 M | - | 95 M | 94.6 M | 93.4 M | 90.7 M | 91 M | 90.4 M | 89.2 M | 80 M | 79.9 M |
Net Income |
1.3 B | 727 M | 1.46 B | 1.39 B | 809 M | 1.34 B | 1.43 B | 722 M | 1.01 B | 968 M | 818 M | - | 1.32 B | 852 M | 974 M | - | 1.63 B | 3.1 B | 1.12 B | 1.15 B | 842 M | 897 M | 625 M | 792 M | 670 M | 193 M | 461 M | 820 M | 595 M | 551 M | 478 M | 174 M | 388 M | 388 M | 249 M | 253 M | 265 M | 196 M | 181 M | 155 M | 210 M | 195 M | 76 M | 90.1 M | 90.1 M | 90.1 M | 90.1 M | 96.8 M | 141 M | 87.4 M | 98.9 M | 470 M | 191 M | 76.7 M | 11.7 M | -53.4 M | -62.4 M | -62.5 M | -43.4 M | -33.9 M | -25.5 M |
Revenue |
4.29 B | 3.61 B | 3.75 B | 3.68 B | 3.03 B | 3.72 B | 3.55 B | 3.14 B | 3.36 B | 3.16 B | 3.16 B | - | 2.94 B | 2.86 B | 2.97 B | - | 3.45 B | 5.14 B | 2.53 B | 2.42 B | 2.29 B | 1.95 B | 1.83 B | 1.86 B | 1.74 B | 1.58 B | 1.37 B | 1.93 B | 1.66 B | 1.61 B | 1.51 B | 1.58 B | 1.5 B | 1.47 B | 1.32 B | 1.23 B | 1.22 B | 1.21 B | 1.2 B | 1.1 B | 1.14 B | 999 M | 870 M | 802 M | 726 M | 666 M | 626 M | 610 M | 597 M | 458 M | 440 M | 415 M | 428 M | 304 M | 232 M | 123 M | 103 M | 108 M | 112 M | 106 M | 116 M |
Operating Income |
1.29 B | 643 M | 1.03 B | 1.08 B | 592 M | 1.18 B | 1.07 B | 751 M | 1.11 B | 1.02 B | 947 M | - | 1.22 B | 1.11 B | 1.26 B | - | 1.85 B | 3.35 B | 1.11 B | - | 1.05 B | 656 M | 700 M | - | 738 M | 316 M | 480 M | - | 627 M | 622 M | 567 M | - | 560 M | 550 M | 431 M | - | 363 M | 292 M | 329 M | - | 392 M | 345 M | 284 M | 216 M | 824 M | 216 M | 216 M | - | 237 M | 158 M | 153 M | - | 202 M | 87.5 M | 22.2 M | - | -58.5 M | -60.3 M | -41 M | -32.1 M | -23.7 M |
Interest Expense |
245 M | 201 M | 756 M | 443 M | 322 M | 327 M | 573 M | -34.6 M | 17.6 M | 85.3 M | 18 M | - | 15.3 M | 13.1 M | 13.6 M | - | 14.2 M | 14.4 M | 14.6 M | - | 26.3 M | 9.7 M | 6.1 M | - | 7.8 M | 8 M | 7.7 M | - | 7.4 M | 6.9 M | 6.4 M | - | 6.18 M | 5.4 M | 7.5 M | - | 3.58 M | 1.88 M | 3.48 M | - | 1.72 M | 2.75 M | 6.17 M | - | 9.23 M | 10.2 M | 11.6 M | - | 11.7 M | 11.4 M | 11.7 M | - | 11.4 M | 11.2 M | 11.2 M | - | 4.06 M | 4.05 M | 3.72 M | 2.23 M | 2.34 M |
EBITDA |
1.54 B | 766 M | 1.43 B | - | 719 M | - | - | 866 M | - | - | 1.05 B | - | 1.46 B | 1.11 B | 1.33 B | - | 2.06 B | 3.35 B | 1.18 B | - | 1.23 B | 771 M | 756 M | - | 894 M | 419 M | 531 M | - | 732 M | 692 M | 604 M | - | 671 M | 624 M | 469 M | - | 439 M | 340 M | 352 M | - | 444 M | 376 M | 300 M | 216 M | 862 M | 240 M | 227 M | - | 267 M | 177 M | 162 M | - | 230 M | 105 M | 30.6 M | - | -35.3 M | -45.4 M | -34 M | -18.5 M | -15 M |
General and Administrative Expenses |
662 M | 648 M | 658 M | 634 M | 633 M | 714 M | 759 M | 689 M | 640 M | 652 M | 601 M | - | 529 M | 476 M | 450 M | - | 445 M | 415 M | 406 M | - | 327 M | 348 M | 367 M | - | 304 M | 295 M | 291 M | - | 369 M | 365 M | 331 M | - | 307 M | 307 M | 297 M | - | 270 M | 292 M | 290 M | - | 210 M | 175 M | 159 M | 175 M | 519 M | 175 M | 175 M | - | 97.6 M | 72.5 M | 77.3 M | - | 46.9 M | 47.7 M | 58.4 M | - | 32.9 M | 24.6 M | 23.4 M | 15.7 M | 14.7 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Regeneron Pharmaceuticals (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
Australia
China
Israel
France
Canada
